Gene transduction of tristetraprolin or its active domain reduces TNF-α production by Jurkat T cells

International Journal of Molecular Medicine

Volumn 17, Issue 5, 2006, Pages 801-809

  Suzuki, Eiji ^a,b   Tsutsumi, Akito ^a   Goto, Daisuke ^a   Matsumoto, Isao ^a   Ito, Satoshi ^a   Otsu, Makoto ^a   Onodera, Masafumi ^a   Takahashi, Satoru ^a   Sato, Yukio ^b   Sumida, Takayuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

AU rich element; Post transcriptional regulation; Retrovirus vector; Rheumatoid arthritis

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; MESSENGER RNA; MYC PROTEIN; PHYTOHEMAGGLUTININ; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; ZINC FINGER PROTEIN;

ANIMAL; APOPTOSIS; ARTICLE; BINDING SITE; CELL LINE; CELL PROLIFERATION; CELL STRAIN 3T3; DRUG EFFECT; GENE EXPRESSION; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HUMAN; LEUKEMIA CELL LINE; METABOLISM; MOUSE; PHYSIOLOGY; RETROVIRUS; TIME;

ANIMALS; APOPTOSIS; BINDING SITES; CELL LINE; CELL PROLIFERATION; GENE EXPRESSION; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; GREEN FLUORESCENT PROTEINS; HUMANS; JURKAT CELLS; MICE; NIH 3T3 CELLS; PHYTOHEMAGGLUTININS; PROTO-ONCOGENE PROTEINS C-MYC; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; RNA, MESSENGER; TIME FACTORS; TRANSFECTION; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR-ALPHA; ZINC FINGERS;

EID: 33750581563     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.17.5.801     Document Type: Article

References (39)

1. Keffer J, Probrt L, Cazlaris H, et al: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J 13: 4025-4031, 1991.
2. Mori L, Iselin S, De Libero G and Lesslauer W: Attenuation of collagen-induced arthritis in 55 kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol 157: 3178-3182, 1996.
3. Campbell IK, O'Donnell K, Lawlor KE and Wicks IP: Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. J Clin Invest 107: 1519-1527, 2001.
4. Williams RO, Feldmann M and Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89: 9784-9788, 1992.
5. Wooley PH, Dutcher J, Widmer MB and Gillis S: Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice. J Immunol 151: 6602-6607, 1993.
6. Eliott MJ, Maini RN, Feldmann M, et al: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36: 1681-1690, 1993. (Pubitemid 23360007)
7. Holloway AF, Rao S and Shannon MF: Regulation of cytokine gene transcription in the immune system. Mol Immunol 38: 567-580, 2001.
8. Baldwin AS Jr: The transcription factor NF-κB and human disease. J Clin Invest 107: 3-6, 2001. (Pubitemid 32047404)
9. Tak PP and Firestein GS: NF-κB: a key role in inflammatory disease. J Clin Invest 107: 7-11, 2001.
10. Palanki MS: Inhibition of AP-1 and NF-kappa B mediated transcriptional activation: therapeutic potential in autoimmune diseases and structural diversity. Curr Med Chem 9: 219-227, 2002.
11. Clark A: Post-transcriptional regulation of pro-inflammatory gene expression. Arthritis Res 2: 172-174, 2000.
12. Anderson P: Post-transcriptional regulation of tumor necrosis factor α production. Ann Rheum Dis 59 (suppl 1): I3-I5, 2000.
13. Carballo E, Lai WS and Blackshear PJ: Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281: 1001-1005, 1998.
14. Zhang T, Kruys V, Huez G and Gueydan C: AU-rich element-mediated translational control: complexity and multiple activities of trans-activating factors. Biochem Soc Trans 30: 952-958, 2002.
15. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F and Kollias G: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 10: 387-398, 1999.
16. Taylor GA, Lai WS, Oakey RJ, et al: The human TTP protein: sequence, alignment with related proteins, and chromosomal localization of the mouse and human genes. Nucleic Acids Res 19: 3454, 1991.
17. Taylor GA, Carballo E, Lee DM, et al: A pathogenetic role for TNF-α in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin deficiency. Immunity 4: 445-454, 1996. (Pubitemid 26354654)
18. Blackshear PJ: Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem Soc Trans 30: 945-952, 2002.
19. Anderson P, Phillip K, Stoecklin G and Kedersha N: Post-transcriptional regulation of proinflammatory proteins. J Leukoc Biol 76: 42-47, 2004.
20. Carballo E, Lai WS and Blackshear PJ: Evidence that tristetraprolin is physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95: 1891-1899, 2000.
21. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS and Blackshear PJ: Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19: 4311-4323, 1999. (Pubitemid 29242006)
22. Lai WS, Carballo E, Thorn JM, Kennington EA and Blackshear PJ: Interaction of CCCH zinc finger proteins with mRNA. J Biol Chem 275: 17827-17837, 2000.
23. Johnson BA, Geha M and Blackwell TK: Similar but distinct effects of the triststraprolin/TIS11 immediate-early proteins on cell survival. Oncogene 19: 1657-1664, 2000.
24. Johnson BA and Blackwell TK: Multiple tristetraprolin sequence domains required to induce apoptosis and modulate response to TNFα through distinct pathways. Oncogene 21: 4237-4246, 2002.
25. Tsutsumi A, Suzuki E, Adachi Y, et al: Expression of tristetraprolin (G0S24) mRNA, a regulator of tumor necrosis factor-a production, in synovial tissues of patients with rheumatoid arthritis. J Rheumatol 31: 1044-1049, 2004.
26. Suzuki A, Obi K, Urabe T, et al: Feasibility of ex vivo gene therapy for neurological disorders using the new retroviral vector GCDNsap packaged in the vesicular stomatitis virus G protein. J Neurochem 82: 953-960, 2002.
27. Iwama A, Osawa M, Hirasawa R, et al: Reciprocal roles for CCAAT/enhancer binding protein (C/EBP) and PU.1 transcription factors in Langerhans cell commitment. J Exp Med 195: 547-558, 2002.
28. Raghavan A, Robison RL, McNabb J, Miller CR, Williams DA and Bohjanen PR: HuA and tristetraprolin are induced following T cell activation and display distinct but overlapping RNA binding specificities. J Biol Chem 276: 47958-47965, 2001. (Pubitemid 33647144)
29. Onodera M, Ariga T, Kawamura N, et al: Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 91: 30-36, 1998.
30. Onodera M, Nelson DM, Sakiyama Y, Candotti F and Blaese RM: Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trails. Acta Haematol 101: 89-96, 1999.
31. Ory DS, Neugeboren BA and Mulligan RC: A stable human-derived packing cell line for production of high titer retrovirus/ vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 93: 11400-11406, 1996.
32. Robbins PD and Ghivizzani SC: Viral vectors for gene therapy. Pharmacol Ther 80: 35-47, 1998.
33. Stoecklin G, Stoeckle P, Lu M, Huehlemann O and Moroni C: Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. RNA 7: 1578-1588, 2001.
34. Lai WS, Kennington EA and Blacksher PJ: Interactions of CCCH zinc finger proteins with mRNA: non-binding tristetraprolin mutants exert an inhibitory effect on degradation of AU-rich element-containing mRNAs. J Biol Chem 277: 9606-9613, 2002.
35. Bickell M, Cohen RB and Pluznik DH: Post-transcriptional regulation of granulocyte-macrophage colony-stimulating factor synthesis in murine T cells. J Immunol 145: 840-845, 1990.
36. Atasoy U, Watson J, Patel D and Keene JD: ELAV protein HuA (HuR) can redistribute between nucleus and cytoplasm and is upregulated during stimulation and T cell activation. J Cell Sci 111: 3145-3156, 1998.
37. Lu JY and Schneider RJ: Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay. J Biol Chem 279: 12974-12979, 2004.
38. Weinblatt ME: Treatment of rheumatoid arthritis. In: Arthritis and Allied Conditions: A Textbook of Rheumatology. 13th edition. Koopman WJ (ed). Williams & Wilkins, Baltimore, MD, pp1131-1141, 1997.
39. Taylor PC: Anti-TNF alpha therapy for rheumatoid arthritis: An update. Intern Med 42: 15-20, 2003. (Pubitemid 36267658)